Wyniki wyszukiwania - BazTech

Ograniczanie wyników

2 Nukleonika

2 2011

Powiadomienia systemowe

Sesja wygasła!

Znaleziono wyników: 2

Liczba wyników na stronie

Wyniki wyszukiwania

Sortuj według:

Ogranicz wyniki do:

Preparation and primary evaluation of 66Ga-DTPA-chitosan in fibrosarcoma bearing mice

Akhlaghi M., Pourjavadi A.

Nukleonika

2011

Vol. 56, No. 1

41-47

Chitosan was chemically modified by diethylenetetraaminepentaacetic acid (DTPA) in different degrees of modification (DM = 6.1, 10.3, 15.7 and 20.9%). DTPA-chitosans were radiolabeled with gallium-66 radionuclide. The effect of several factors on labeling yield such as degree of modification, acidity and concentration of DTPA-chitosan solution, contact time and radioactivity was investigated. Radiolabeled DTPA chitosans were intratumorally injected to fibrosarcoma bearing mice and the leakage of radioactivity from the injection site was evaluated. In comparison with chitosan, all DTPA chitosans showed better efficiency in preventing the leakage of radioactivity from tumor lesion and DTPA-chitosan (DM = 10.3%) was the best which led to remaining 97% of injected dose in the injection site after 54 h of injection. The highest leaked radioactivity from the injection site was in the lungs, liver, spleen and the kidneys. Our results indicated that the DTPA modified chitosan can be an effective carrier for therapeutic radionuclides for tumor treatment by the intratumoral injection technique.

Preparation and evaluation of a [66Ga]gallium chitosan complex in fibrosarcoma bearing animal models

Pourjavadi A., Akhlaghi M., Jalilian A. R.

Nukleonika

2011

Vol. 56, No. 1

35-40

[66Ga]gallium chitosan complex was prepared with a high radiochemical purity (greater than 99%) in dilute acetic acid solution. The radiochemical purity of [66Ga]gallium chitosan complex was checked by using paper chromatography technique. The prepared complex solution was injected intratumoral to fibrosarcoma-bearing mice and the leakage of radioactivity from injection site was investigated. Approximately, 85.4% of the injected dose was retained in the injection site 54 h after injection and most of the leaked radioactivity was accumulated in the blood, liver (0.5%) and lung (6.5%).